Drug:
Reaction: PRODUCT DOSE OMISSION ISSUE
20250101 - 20251231
No. 301 - 400
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 301 | 25127494 |
US |
1 | |
Product dose omission issue, Product delivery mechanism issue, Product lot number issue, |
||||
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE, |
||||
| 302 | 25127524 |
US |
42 | 2 |
Crohn^s disease, Device leakage, Drug ineffective, Incorrect dose administered, Device defective, Product storage error, Product dose omission issue, |
||||
VEDOLIZUMAB, VEDOLIZUMAB, LEVOTHYROXINE, |
||||
| 303 | 25127546 |
US |
81 | 1 |
Dehydration, Dementia with Lewy bodies, Influenza, Dysphagia, Product dose omission issue, |
||||
PIMAVANSERIN TARTRATE, PIMAVANSERIN TARTRATE, |
||||
| 304 | 25127562 |
US |
1 | |
Memory impairment, Product dose omission issue, |
||||
PIMAVANSERIN TARTRATE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, BENZONATATE, CEPHALEXIN, CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFOLXACIN, CIPROFLOXACIN TABLETS, CLOPIDOGREL, CLOPIDOGREL BISULFATE, CYANOCOBALAMIN, EZETIMIBE, FOLIC ACID, LEVOFLOXACIN, LEVOFLOXACIN IN 5% DEXTROSE, LEVOTHYROXINE, LINACLOTIDE, LOSARTAN, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, MUPIROCIN, MUPIROCIN CALCIUM, PAROXETINE HYDROCHLORIDE HEMIHYDRATE, PAROXETINE, PAROXETINE HYDROCHLORIDE, NIRMATRELVIR AND RITONAVIR, PROMETHAZINE, ERGOCALCIFEROL, |
||||
| 305 | 25127570 |
US |
63 | 2 |
Illness, Dyspnoea, Otorrhoea, Nausea, Respiratory tract congestion, Product dose omission issue, |
||||
MEPOLIZUMAB, LEVOTHYROXINE, AMLODIPINE BESYLATE, FAMOTIDINE, SEMAGLUTIDE, MONTELUKAST, BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, ALBUTEROL SULFATE, ALBUTEROL, CYCLOBENZAPRINE, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, ZOLPIDEM TARTRATE, PREDNISONE, MECLIZINE HCL 12.5 MG, MECLIZINE, MECLIZINE HYDROCHLORIDE, MECLIZINE HCL 25MG, MECLIZINE HCL 12.5MG, BUPROPION HYDROCHLORIDE, BUPROPION, AMOXICILLIN, |
||||
| 306 | 25127671 |
US |
72 | 1 |
Device failure, Product dose omission issue, |
||||
ABATACEPT, |
||||
| 307 | 25127754 |
US |
39 | 1 |
Surgery, Product dose omission issue, |
||||
CABOTEGRAVIR, |
||||
| 308 | 25127789 |
US |
||
Pneumonia, Product dose omission issue, |
||||
LENALIDOMIDE, |
||||
| 309 | 25127993 |
US |
2 | |
Product dose omission issue, |
||||
NIRAPARIB, |
||||
| 310 | 25128007 |
US |
59 | 2 |
Product dose omission issue, Injection site erythema, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 311 | 25128013 |
US |
67 | 1 |
Product dose omission issue, Injection site haemorrhage, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 312 | 25128061 |
US |
70 | 1 |
Product dose omission issue, Pruritus, Rash, Dry skin, |
||||
LENALIDOMIDE, |
||||
| 313 | 25128072 |
US |
2 | |
Product dose omission issue, Memory impairment, |
||||
APREMILAST, |
||||
| 314 | 25128079 |
US |
||
Prostatic specific antigen increased, Full blood count abnormal, Product dose omission issue, Hypertension, Fatigue, |
||||
ACALABRUTINIB, |
||||
| 315 | 25128138 |
US |
2 | |
Product dose omission issue, Burning sensation, |
||||
INTERFERON BETA-1A, INTERFERON BETA-1A, INTERFERON BETA-1A, INTERFERON BETA-1A, INTERFERON BETA-1A, INTERFERON BETA-1A, INTERFERON BETA-1A, INTERFERON BETA-1A, INTERFERON BETA-1A, INTERFERON BETA-1A, INTERFERON BETA-1A, INTERFERON BETA-1A, INTERFERON BETA-1A, |
||||
| 316 | 25128168 |
US |
46 | 2 |
Product dose omission issue, Wrong technique in product usage process, Sinusitis, Pain, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, |
||||
| 317 | 25128187 |
CA |
2 | |
Liver disorder, Rash macular, Product dose omission issue, |
||||
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE TABLETS, |
||||
| 318 | 25128197 |
US |
68 | 1 |
Needle issue, Product colour issue, Product dose omission issue, |
||||
GOLIMUMAB, GOLIMUMAB, |
||||
| 319 | 25128220 |
US |
2 | |
Product dose omission issue, Product delivery mechanism issue, |
||||
FLUTICASONE PROPIONATE, |
||||
| 320 | 25128221 |
US |
57 | |
Needle issue, Product dose omission issue, |
||||
GUSELKUMAB, |
||||
| 321 | 25128278 |
GB |
2 | |
Illness, Product dose omission issue, |
||||
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, |
||||
| 322 | 25128282 |
US |
2 | |
Product dose omission issue, Product use complaint, Product delivery mechanism issue, |
||||
MEDROXYPROGESTERONE ACETATE, |
||||
| 323 | 25128300 |
CA |
1 | |
Pain, Product dose omission issue, |
||||
ADALIMUMAB-ADAZ, |
||||
| 324 | 25128310 |
US |
||
Product dose omission issue, Device malfunction, Injection site bruising, |
||||
MEDROXYPROGESTERONE ACETATE, |
||||
| 325 | 25128314 |
US |
2 | |
Product dose omission issue, Product use complaint, Product quality issue, Device malfunction, |
||||
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE, |
||||
| 326 | 25128330 |
US |
||
Product dose omission issue, Device malfunction, Product use complaint, |
||||
MEDROXYPROGESTERONE ACETATE, |
||||
| 327 | 25128338 |
US |
1 | |
Product dose omission issue, Product use issue, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 328 | 25128339 |
US |
70 | 2 |
Liver transplant, Product dose omission issue, |
||||
TENOFOVIR ALAFENAMIDE, |
||||
| 329 | 25128362 |
GB |
1 | |
Tuberculosis, Liver function test abnormal, Product dose omission issue, |
||||
GOLIMUMAB, TIRZEPATIDE, |
||||
| 330 | 25128586 |
US |
71 | 2 |
Product dose omission issue, Off label use, |
||||
| 331 | 25128631 |
US |
70 | 2 |
Incorrect dose administered, Product dose omission issue, Off label use, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 332 | 25128667 |
US |
||
Liquid product physical issue, Product dose omission issue, Product use complaint, Device malfunction, |
||||
MEDROXYPROGESTERONE ACETATE, |
||||
| 333 | 25128668 |
US |
||
Product dose omission issue, Product use complaint, Liquid product physical issue, Device malfunction, |
||||
MEDROXYPROGESTERONE ACETATE, |
||||
| 334 | 25128692 |
US |
2 | |
Nasal congestion, Product dose omission issue, |
||||
BELIMUMAB, |
||||
| 335 | 25128998 |
US |
11 | 1 |
Pruritus, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 336 | 25129096 |
US |
1 | |
Cerebrovascular accident, Somnolence, Pain in extremity, Decreased appetite, Asthenia, Fatigue, Arthralgia, Rash, Constipation, Diarrhoea, Product dose omission issue, |
||||
IXAZOMIB, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, |
||||
| 337 | 25129108 |
US |
62 | 1 |
Drug ineffective, Product dose omission issue, |
||||
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, PEGLOTICASE, |
||||
| 338 | 25129109 |
US |
1 | |
Drug ineffective, Product dose omission issue, |
||||
FLUTICASONE PROPIONATE, ALBUTEROL SULFATE, ALBUTEROL, MONTELUKAST SODIUM, |
||||
| 339 | 25129127 |
US |
2 | |
Urticaria, Product dose omission issue, |
||||
BACLOFEN, GABAPENTIN, MAGNESIUM, CELECOXIB, DULOXETINE HYDROCHLORIDE, DULOXETIN HYDROCHLORIDE, DULOXETINE, |
||||
| 340 | 25129128 |
US |
67 | 2 |
Product dose omission issue, Malaise, |
||||
PREDNISONE, FOLIC ACID, EMPAGLIFLOZIN, METHOTREXATE SODIUM, EXTENDED PHENYTOIN SODIUM, HYDROXYCHLOROQUINE SULFATE, OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN, FAMOTIDINE, ERGOCALCIFEROL, FLUTICASONE FUROATE, |
||||
| 341 | 25129129 |
US |
2 | |
Skin lesion, Skin hyperpigmentation, Product dose omission issue, |
||||
IBANDRONATE SODIUM, BACLOFEN, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, ASPIRIN, ACETAMINOPHEN, ASPIRIN, AND CAFFEINE, ACETAMINOPHEN, ASPIRIN (NSAID) AND CAFFEINE, ERGOCALCIFEROL, PREDNISONE, FOLIC ACID, |
||||
| 342 | 25129138 |
US |
58 | 1 |
Rash, Product dose omission issue, Product use in unapproved indication, |
||||
PREDNISONE, RITUXIMAB AND HYALURONIDASE, AZATHIOPRINE, LOSARTAN POTASSIUM, LOSARTAN, LORATADINE, LORATADINE TABLET, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, METFORMIN HYDROCHLORIDE, METFORMIN, METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, METFORMIN HYDROCHLORIDE TABLET, METFORMIN HYDROCHLORIDE TABLETS, METOPROLOL TARTRATE, METOROPROLOL TARTRATE, METOPROLOL, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, |
||||
| 343 | 25129139 |
US |
9 | 1 |
Rash erythematous, Rash pruritic, Skin warm, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 344 | 25129151 |
US |
1 | |
Dyspnoea, Ill-defined disorder, Overdose, Product dose omission issue, |
||||
FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, |
||||
| 345 | 25129248 |
US |
2 | |
Jaw disorder, Product dose omission issue, |
||||
CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES, CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES, ERGOCALCIFEROL, PROGESTERONE, ARMODAFINIL, |
||||
| 346 | 25129310 |
US |
77 | 2 |
Swelling face, Eye swelling, Pain, Insomnia, Product dose omission issue, |
||||
AVAPRITINIB, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, FUROSEMIDE, METOPROLOL TARTRATE, METOROPROLOL TARTRATE, METOPROLOL, |
||||
| 347 | 25129333 |
US |
36 | 2 |
Product dose omission issue, Diabetes mellitus, Contraindicated product administered, |
||||
ESCITALOPRAM OXALATE, ESCITALOPRAM, ROSUVASTATIN CALCIUM, LOSARTAN POTASSIUM, LOSARTAN, DAPAGLIFLOZIN, ERGOCALCIFEROL, VITAMIN C, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, DEXLANSOPRAZOLE, WARFARIN SODIUM, WARFARIN, FAMOTIDINE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, VITAMIN E, CREAM, FUROSEMIDE, THIAMINE HYDROCHLORIDE, RIBOFLAVIN 5 PHOSPHATE SODIUM, DEXPANTHENOL AND NIACINAMIDE, |
||||
| 348 | 25129334 |
US |
66 | 2 |
Contraindicated product administered, Contusion, Eye pain, Vision blurred, Aspartate aminotransferase increased, Alanine aminotransferase increased, Pancreatitis, Nephrolithiasis, Lipase increased, Product dose omission issue, Lacrimation increased, Amblyopia, Abdominal pain, Fluid retention, Blood albumin decreased, Product use in unapproved indication, Drug ineffective for unapproved indication, Cataract, |
||||
METHOTREXATE, METHOTREXATE SODIUM, LEVOTHYROXINE, ALENDRONATE SODIUM, ALENDRONATE SODIUM TABLET, TOPIRAMATE, TOPIRAMATE SPINKLE, ZIPRASIDONE, GABAPENTIN, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, PREDNISONE, ONABOTULINUMTOXINA, SUMATRIPTAN, BUPROPION HYDROCHLORIDE, METHOCARBAMOL, METHOCARBAMOL TABLETS, SERTRALINE, |
||||
| 349 | 25129368 |
US |
70 | 2 |
Cataract, Eye infection, Swelling, Muscle spasms, Product dose omission issue, |
||||
DULAGLUTIDE, GLIPIZIDE, DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE, ALLOPURINOL, LUBIPROSTONE, OLMESARTAN MEDOXOMIL, |
||||
| 350 | 25129444 |
US |
43 | 2 |
Product dose omission issue, Device issue, Accidental exposure to product, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, CYCLOSPORINE, CYCLOSPORINE, FAMOTIDINE, CETIRIZINE HYDROCHLORIDE, |
||||
| 351 | 25129504 |
US |
69 | 2 |
Osteoarthritis, Product dose omission issue, |
||||
TOFACITINIB, |
||||
| 352 | 25129571 |
US |
||
Product dose omission issue, Pneumonia bacterial, |
||||
| 353 | 25129646 |
US |
60 | 2 |
Renal impairment, Product dose omission issue, |
||||
TOFACITINIB, |
||||
| 354 | 25129749 |
US |
65 | 2 |
Device operational issue, Product dose omission issue, |
||||
ABATACEPT, MELOXICAM, FOLIC ACID, DULOXETINE HYDROCHLORIDE, DULOXETINE, ROSUVASTATIN, LEFLUNOMIDE, PREDNISONE, |
||||
| 355 | 25129773 |
US |
2 | |
Death, Product dose omission issue, Off label use, |
||||
MAGNESIUM, CALCIUM, |
||||
| 356 | 25129823 |
US |
2 | |
Product dose omission issue, Device difficult to use, Incorrect dose administered, Product delivery mechanism issue, |
||||
FLUTICASONE PROPIONATE, |
||||
| 357 | 25129850 |
US |
24 | 2 |
Hereditary angioedema, Hereditary angioedema, Hereditary angioedema, Product dose omission issue, |
||||
| 358 | 25129889 |
CO |
37 | 2 |
Chronic myeloid leukaemia recurrent, Leukocytosis, White blood cell count decreased, Splenomegaly, Staphylococcal infection, Weight decreased, Decreased immune responsiveness, Asthenia, Myalgia, Chest pain, Product supply issue, Product dose omission issue, Inappropriate schedule of product administration, Ill-defined disorder, Peripheral swelling, Skin discolouration, Dizziness, Malaise, Fatigue, Abdominal distension, Illness, |
||||
NILOTINIB, NILOTINIB, NILOTINIB, NILOTINIB, NILOTINIB, NILOTINIB, NILOTINIB, ALLOPURINOL, CEPHALEXIN, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, |
||||
| 359 | 25129899 |
US |
71 | 1 |
Atrial fibrillation, Product dose omission issue, Hot flush, |
||||
DAROLUTAMIDE, DAROLUTAMIDE, |
||||
| 360 | 25129981 |
US |
||
Product dose omission issue, |
||||
USTEKINUMAB, |
||||
| 361 | 25129984 |
US |
1 | |
Product dose omission issue, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 362 | 25130000 |
US |
86 | 1 |
Toe amputation, Product dose omission issue, Product prescribing issue, |
||||
FOSTAMATINIB, |
||||
| 363 | 25130030 |
US |
||
Product dose omission issue, Product use issue, No adverse event, |
||||
PREDNISOLONE ACETATE, |
||||
| 364 | 25130073 |
US |
35 | 1 |
Product dose omission issue, Stress, Memory impairment, |
||||
LENALIDOMIDE, ACYCLOVIR, OXYCODONE, SULFAMETHOXAZOLE AND TRIMETHOPRIM, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, FUROSEMIDE, POTASSIUM PHOSPHATE, MONOBASIC, ERGOCALCIFEROL, |
||||
| 365 | 25130093 |
US |
1 | |
Dyspepsia, Product dose omission issue, Device leakage, |
||||
SOMATROPIN, SOMATROPIN, |
||||
| 366 | 25130241 |
US |
2 | |
Abnormal dreams, Nightmare, Product dose omission issue, |
||||
IRON, ALPRAZOLAM, SERTRALINE, |
||||
| 367 | 25130398 |
US |
1 | |
Nephrolithiasis, Product dose omission issue, |
||||
SECUKINUMAB, |
||||
| 368 | 25130465 |
US |
74 | 2 |
Hypotension, Product dose omission issue, |
||||
SACUBITRIL AND VALSARTAN, TREPROSTINIL, RIOCIGUAT, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, METOPROLOL TARTRATE, METOPROLOL, |
||||
| 369 | 25130523 |
US |
2 | |
Pain, Product dose omission issue, |
||||
BELIMUMAB, |
||||
| 370 | 25130666 |
US |
2 | |
Full blood count decreased, Wrong technique in product usage process, Product dose omission issue, |
||||
NIRAPARIB, NIRAPARIB, |
||||
| 371 | 25130734 |
US |
60 | 2 |
Rheumatoid arthritis, Gait disturbance, Product dose omission issue, |
||||
ABATACEPT, |
||||
| 372 | 25130813 |
US |
1 | |
Product dose omission issue, |
||||
FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, |
||||
| 373 | 25130819 |
US |
2 | |
Abortion spontaneous, Maternal exposure during pregnancy, Product dose omission issue, |
||||
CERTOLIZUMAB PEGOL, |
||||
| 374 | 25130839 |
US |
||
Product dose omission issue, |
||||
GUSELKUMAB, GUSELKUMAB, GUSELKUMAB, GUSELKUMAB, |
||||
| 375 | 25130898 |
US |
15 | 1 |
Product dose omission issue, Product knowledge deficit, |
||||
SOMATROPIN, SOMATROPIN, |
||||
| 376 | 25131192 |
US |
63 | 1 |
Diabetes mellitus inadequate control, Pruritus, Diarrhoea, Toothache, Bipolar disorder, Nasal discomfort, Weight decreased, Somnolence, Arthritis, Lacrimation increased, Dry mouth, Intentional product use issue, Product dose omission issue, Rhinorrhoea, Influenza, Blood glucose decreased, Wrong technique in product usage process, Drug ineffective, Inability to afford medication, |
||||
DEUTETRABENAZINE, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, ARIPIPRAZOLE ORALLY DISINTEGRATING, ARIPIPRAZOLE, ARIPIPRAZOLE ORAL, MAGNESIUM, MELATONIN, |
||||
| 377 | 25131229 |
US |
1 | |
Product dose omission issue, |
||||
FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, |
||||
| 378 | 25131231 |
US |
56 | 2 |
Dyskinesia, Product use in unapproved indication, Paranasal sinus discomfort, Laboratory test abnormal, Product dose omission issue, Dysarthria, Feeling abnormal, |
||||
DEUTETRABENAZINE, DEUTETRABENAZINE, SPIRONOLACTONE, GABAPENTIN, PROGESTERONE, |
||||
| 379 | 25131260 |
US |
||
Product dose omission issue, Device defective, |
||||
USTEKINUMAB, USTEKINUMAB, |
||||
| 380 | 25131275 |
US |
1 | |
Product dose omission issue, |
||||
MEPOLIZUMAB, |
||||
| 381 | 25131331 |
GB |
1 | |
Post procedural complication, Product dose omission issue, |
||||
VEDOLIZUMAB, VEDOLIZUMAB, |
||||
| 382 | 25131339 |
US |
1 | |
Product dose omission issue, Product storage error, |
||||
INFLIXIMAB, |
||||
| 383 | 25131427 |
GB |
2 | |
Device defective, Product dose omission issue, |
||||
USTEKINUMAB, USTEKINUMAB, |
||||
| 384 | 25131559 |
US |
58 | 1 |
Blood glucose increased, Visual impairment, Product dose omission issue, |
||||
INSULIN LISPRO, INSULIN LISPRO, |
||||
| 385 | 25131593 |
US |
56 | 2 |
Injection site pain, Product dose omission issue, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 386 | 25131636 |
CA |
72 | 2 |
Illness, Viral infection, Product dose omission issue, |
||||
RITUXIMAB, RITUXIMAB, |
||||
| 387 | 25131688 |
77 | ||
Product dose omission issue, |
||||
RUXOLITINIB, |
||||
| 388 | 25131689 |
64 | ||
Product dose omission issue, |
||||
RUXOLITINIB, |
||||
| 389 | 25131706 |
US |
72 | 2 |
Azotaemia, Product dose omission issue, |
||||
| 390 | 25131836 |
US |
53 | 2 |
Product dose omission issue, Injection site pain, |
||||
GALCANEZUMAB-GNLM, GALCANEZUMAB-GNLM, |
||||
| 391 | 25131867 |
DE |
||
Device issue, Product dose omission issue, |
||||
USTEKINUMAB, USTEKINUMAB, |
||||
| 392 | 25131879 |
US |
||
Product dose omission issue, |
||||
ESKETAMINE HYDROCHLORIDE, |
||||
| 393 | 25131947 |
US |
||
Product dose omission issue, |
||||
GUSELKUMAB, GUSELKUMAB, GUSELKUMAB, GUSELKUMAB, |
||||
| 394 | 25131950 |
US |
2 | |
Depression, Feeling abnormal, Product dose omission issue, |
||||
BELIMUMAB, BELIMUMAB, DULOXETINE HYDROCHLORIDE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE SULFATE AND AMPHETAMINE ASPARTATE, EMPAGLIFLOZIN, SPIRONOLACTONE, FUROSEMIDE, LEVOTHYROXINE, HYDROXYCHLOROQUINE, GABAPENTIN, LISINOPRIL, INSULIN ASPART, |
||||
| 395 | 25131973 |
US |
48 | 2 |
Product dose omission issue, Injection site pain, |
||||
DULAGLUTIDE, DULAGLUTIDE, DULAGLUTIDE, DULAGLUTIDE, |
||||
| 396 | 25132012 |
US |
2 | |
Device defective, Product dose omission issue, |
||||
USTEKINUMAB, USTEKINUMAB, |
||||
| 397 | 25132016 |
US |
43 | 2 |
Product dose omission issue, Injection site pain, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 398 | 25132033 |
GB |
2 | |
Psoriatic arthropathy, Product availability issue, Product dose omission issue, |
||||
CERTOLIZUMAB PEGOL, |
||||
| 399 | 25120957 |
US |
||
Dyspnoea, Product dose omission issue, Illness, Tremor, |
||||
BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, |
||||
| 400 | 25120958 |
FR |
55 | 2 |
Product dose omission issue, Device deployment issue, |
||||
GOLIMUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28